Adenovirus Biodistribution is Modified in Sensitive Animals Compared to Naïve Animals

Molecular Biotechnology
Ana Sandoval-RodríguezJ Armendariz-Borunda

Abstract

Pre-existing immune response against adenovirus could diminish transgene expression efficiency when Ad is employed in humans as gene therapy vector. We previously used Ad-hΔuPA (Recombinant adenovirus expressing human urokinase-type plasminogen activator) as antifibrotic gene therapy in cirrhosis models and demonstrated its effectiveness. As a further clinical approach, transient Cyclosporine A (CsA) immunosuppression was induced in cirrhotic animals to determine whether Ad-hΔuPA administration retained efficacy. Adenovirus sensitization was achieved by systemic administration of non-therapeutic Ad-βGal (Recombinant adenovirus expressing beta-galactosidase) after 4 weeks of intraperitoneal carbon tetrachloride (CCl4) regimen. Cirrhosis induction continued up to 8 weeks. At the end of CCl4 intoxication, immunosuppression was achieved with three CsA doses (40 mg/kg) as follows: 24 h before administration of Ad-hΔuPA, at the moment of Ad-hΔuPA injection and finally, 24 h after Ad-hΔuPA inoculation. At 2 and 72 h after Ad-hΔuPA injection, animals were sacrificed. Liver, spleen, lung, kidney, heart, brain, and testis were analyzed for Ad-biodistribution and transgene expression. In naïve animals, Ad-hΔuPA genomes prevailed in liver ...Continue Reading

References

Jan 1, 1989·Pharmacology & Therapeutics·R O RecknagelR L Waller
Jun 1, 1995·Journal of Hepatology·K IshakR N MacSween
Apr 29, 1997·Proceedings of the National Academy of Sciences of the United States of America·M A KayC B Wilson
Oct 27, 1997·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Y IlanJ Roy-Chowdhury
Dec 22, 2000·Molecular Therapy : the Journal of the American Society of Gene Therapy·S SalgadoJ Armendariz-Borunda
May 18, 2001·Molecular Therapy : the Journal of the American Society of Gene Therapy·Y ZhangJ M Wilson
May 7, 2002·Journal of Virology·Andrei N VarnavskiJames M Wilson
Sep 17, 2002·Molecular Therapy : the Journal of the American Society of Gene Therapy·Maria T VlachakiBin S The
May 21, 2003·Gene Therapy·Q Liu, D A Muruve
Jan 27, 2004·Molecular Therapy : the Journal of the American Society of Gene Therapy·Alejandra Miranda-DíazJuan Armendáriz-Borunda
Feb 24, 2004·The Journal of Gene Medicine·Oliver Meier, Urs F Greber
Jun 15, 2004·Molecular Therapy : the Journal of the American Society of Gene Therapy·Jeffrey S SmithAndrew P Byrnes
Jul 9, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Valder R ArrudaJonathan D Finn
Jan 21, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Antonio FontanellasIgnacio Melero
Apr 2, 2011·Current Gene Therapy·Yadvinder S AhiSuresh K Mittal
Aug 23, 2011·Journal of Bioscience and Bioengineering·Juan Armendáriz-BorundaJesús García-Bañuelos
Oct 8, 2011·PLoS Pathogens·Latha P GanesanClark L Anderson
Oct 14, 2011·Viruses·Sergey S Seregin, Andrea Amalfitano
Jan 30, 2015·Acta Cirúrgica Brasileira·Giorgio Alfredo Pedroso BarettaJorge Eduardo Fouto Matias
Sep 21, 2018·Proceedings of the National Academy of Sciences of the United States of America·P J Klasse

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.